Sarah
Cannon, an affiliate of one of the leading healthcare providers in
America, Hospital
Corporation of America (HCA), announced today that its Chief Medical
Officer and Executive Director, Drug Development, Howard
A. Burris III, MD, has been named one of OncLive's 2014 "Giants of
Cancer Care." OncLive, which is the official home of Oncology &
Biotech News, OncologyLive and several other industry publications,created the award program to recognize and celebrate individuals who
have achieved landmark success within the field of oncology.

Howard A. Burris III, MD, Chief Medical Officer and Executive Director, Drug Development, of Sarah Cannon has been named one of OncLive's 2014 "Giants of Cancer Care." (Photo: Business Wire)

Dr. Burris is one of 16 luminaries nationwide selected by oncology peers
for his remarkable achievements in research and clinical practice, which
includes specific recognition for his initiation of one of the largest
investigational drug development programs for cancer.

"For more than 2 years, Dr. Burris has been devoted to the advancement
of therapies for patients through innovative cancer research and care,"
said Sarah Cannon's Chief Executive Officer, Dee Anna Smith.
"Recognition from this esteemed panel of oncology advisors is an
incredible honor - and we are proud to have Dr. Burris guiding our
clinical programs, as he has made significant contributions to the
development of new agents that have transformed cancer treatment options
worldwide."

Under Dr. Burris' leadership, the Sarah Cannon Research Institute has
conducted more than 130 first-in-man clinical trials and made an impact
on more than half of the new cancer therapies approved in the last 10
years. Beyond his cancer research contributions, Dr. Burris oversees the
company's integrated services that pair research with the delivery of
physician-led and patient-centric cancer care.

Giants of Cancer Care are chosen by an exclusive advisory board of 29
oncology educators, clinicians and researchers. Advisory Board members
have dedicated their valuable time to the program, providing guidance to
OncLive as it further develops the program and, most importantly,
selects the oncologists who will be named Giants. In evaluating criteria
for selection to the inaugural class of Giants, the Advisory Board
considered individuals who have made a significant contribution to
patient care, clinical trials or translational research.

OncLive Chairman and CEO Mike Hennessy said, "It is our distinct
privilege to honor these unsung medical heroes. It is our mission to
continue recognizing the leaders in the oncology field for their
remarkable achievements in research and clinical practice."

The 2014 Giants of Cancer Care were announced and honored at an
invitation-only reception Friday, May 30 in Chicago. Each Giant will be
individually profiled in a special edition of OncologyLive and
prominently featured on OncLive.com.

About Sarah Cannon

Sarah Cannon, the cancer enterprise of the Hospital Corporation of
America (HCA), advances science and transforms care in communities
across the United States and United Kingdom. While the care service line
was launched in 2011, Sarah Cannon has had a rich history in clinical
research beginning in 1993 when its research investigators brought
clinical trials into the community setting. The global network's cancer
care reach includes individualized patient navigation provided by
oncology-trained nurse navigators, experience conducting more than 130
first-in-man clinical trials, more than 850 stem cell transplants
performed annually throughout the Sarah Cannon Blood Cancer Network and
the first community-based molecular profiling program. Through its
programs, Sarah Cannon is providing state-of-the- art cancer care close
to home for hundreds of thousands of patients, a number unmatched by any
single cancer center.

OncLive.com is the official website for Intellisphere's Oncology
Specialty Group, which publishes Oncology & Biotech News,
OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Contemporary
Oncology. The mission of OncLive® and its family
of publications is to provide oncology professionals with the resources
and information they need in order to provide the best care for their
patients. The Oncology Specialty Group is a division of Intellisphere,
LLC, a leading provider of health care publishing, research and
education. To learn more, please visitwww.OncLive.com.